Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.

Inclusion Criteria: * Cytological or histological proven NSCLC stage III or inoperable stage II, cT1-2a-3N1-3M0 with peripheral tumors \< 5 cm (chest wall infiltration is no exclusion criteria if the tumor diameter is \< 5 cm). * Weight loss \< 10% in the last three months * WHO-performance status ≤ 2 * Patients that receive concurrent chemoradiotherapy, with the exception of adriamycin and gemcitabine * FEV1 and DLCO \> 40 % of the age-adjusted normal value * Minimum required laboratory data bone marrow reserve and hepatic- and renal function * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Before patient registration, written informed consent must be given according to GCP and national regulations Exclusion criteria: * Patients with central tumors \< 2 cm of the proximal bronchial tree (Figure 2) or tumors immediately adjacent to mediastinal or pericardial pleura. * Patients that receive sequential chemoradiotherapy or radiotherapy only. * Patients with grade 3 dyspnea at baseline (according to CTCAE version 4.03) * Patients with Pancoast tumors * Prior radiotherapy treatment to the thorax * Any contraindications to the administration of thoracic radiotherapy * Pregnant women